Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease
Belite Bio NASDAQ: BLTE Chief Medical Officer Hendrik Scholl said the company is advancing its lead compound, Tinlarebant, as a potential treatment for Stargardt disease and geographic atrophy secondary to age-related macular degeneration, two severe retinal diseases with overlapping features.
Belite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Belite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript
Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript
Belite Bio Q1 Earnings Call Highlights
Belite Bio NASDAQ: BLTE said it has begun a rolling New Drug Application submission to the U.S. Food and Drug Administration for Tinlarebant in Stargardt disease, while also accelerating preparations for a potential commercial launch.
Belite Bio, Inc (BLTE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Belite Bio, Inc (BLTE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Belite Bio, Inc (BLTE) Q4 2025 Earnings Call Transcript
Belite Bio, Inc (BLTE) Q4 2025 Earnings Call Transcript
Belite Bio's drug for genetic eye disease meets main goal in late-stage trial
Belite Bio said on Monday that its experimental drug for a rare genetic eye disease met the main goal in a late-stage study.
Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript
Belite Bio, Inc ( BLTE ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Julie Fallon Yu-Hsin Lin - Chairman of the Board of Directors & CEO Hao-Yuan Chuang - CFO & Director Nathan L. Mata - Chief Scientific Officer Hendrik Scholl - Chief Medical Officer Conference Call Participants Yi Chen - H.C.
Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript
Belite Bio, Inc (NASDAQ:BLTE ) Q2 2025 Earnings Conference Call August 11, 2025 4:30 PM ET Company Participants Hao-Yuan Chuang - CFO & Director Hendrik P.N. Scholl - Chief Medical Officer Nathan L.
Belite Bio: Investors Face Tricky Decision Ahead Of Key STGD1 Study Readout
Belite Bio's lead drug, Tinlarebant, shows promise in rare eye diseases, but pivotal data and regulatory approval remain at least 18 months away in my view. The DRAGON study's interim analysis is encouraging, but assumptions of success are risky given the small STGD1 market and lack of robust clinical data. Belite's $2bn valuation appears to price in success for both STGD1 and GA, yet GA efficacy data is lacking and competition is fierce.
Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript
Belite Bio, Inc (NASDAQ:BLTE ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Julie Fallon - Investor Relations Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hendrik Scholl - Chief Medical Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Basma Radwan - Leerink Partners Jennifer Kim - Cantor Yi Chen - HCW Bruce Jackson - Benchmark Michael Okunewitch - Maxim Operator Ladies and gentlemen, thank you for joining us, and welcome to the Belite Bio First Quarter 2025 Earnings Call. After today's prepared remarks, we will host a question-and-answer session.
Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript
Belite Bio, Inc. (NASDAQ:BLTE ) Q4 2024 Results Conference Call March 17, 2025 4:30 PM ET Company Participants Julie Fallon - Investor Relations Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hendrik Scholl - Chief Medical Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Jennifer Kim - Cantor Basma Radwan - Leerink Partners Yi Chen - H.C. Wainwright Bruce Jackson - Benchmark Michael Okunewitch - Maxim Group Operator Ladies and gentlemen, thank you for joining us, and welcome to the Belite Bio Fourth Quarter and Full Year 2024 Earnings Conference Call.
